Acquisition by Paulson Richard A. of 24900 shares of Bluebird Bio subject to Rule 16b-3
BLUE Stock | USD 6.42 6.04 1,589% |
About 58% of Bluebird Bio's investor base is looking to short. The analysis of the overall investor sentiment regarding Bluebird bio suggests that many traders are alarmed. The current market sentiment, together with Bluebird Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use Bluebird bio stock news signals to limit their universe of possible portfolio assets.
Bluebird |
Filed transaction by Bluebird bio Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at finance.yahoo.com
Bluebird Bio Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Bluebird Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bluebird Bio Fundamental Analysis
We analyze Bluebird Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bluebird Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bluebird Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Bluebird Bio is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Bluebird bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bluebird Bio stock to make a market-neutral strategy. Peer analysis of Bluebird Bio could also be used in its relative valuation, which is a method of valuing Bluebird Bio by comparing valuation metrics with similar companies.
Peers
Bluebird Bio Related Equities
MDGL | Madrigal Pharmaceuticals | 0.67 | ||||
AGIO | Agios Pharm | 0.39 | ||||
VIR | Vir Biotechnology | 0.40 | ||||
SRPT | Sarepta Therapeutics | 0.61 | ||||
CVAC | CureVac NV | 1.25 | ||||
ZNTL | Zentalis Pharmaceuticals | 1.28 | ||||
VKTX | Viking Therapeutics | 1.75 | ||||
PTCT | PTC Therapeutics | 2.09 | ||||
KPTI | Karyopharm Therapeutics | 2.78 | ||||
TVTX | Travere Therapeutics | 3.29 | ||||
YMAB | Y MAbs | 3.79 | ||||
HEPA | Hepion Pharmaceuticals | 4.84 | ||||
KRYS | Krystal Biotech | 5.07 | ||||
MRSN | Mersana Therapeutics | 6.52 |
Complementary Tools for Bluebird Stock analysis
When running Bluebird Bio's price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |